SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Teva’s celiac drug meets main goal in mid-stage trial

Teva said its experimental immune-disorder drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the main goal of its mid-stage trial. U.S.-listed shares were up over 4% in premarket.

TEVA

Teva Pharmaceutical Industries TASE:TEVA said on Wednesday its experimental drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the main goal of a mid-stage trial. U.S.-listed shares of the company were up over 4% in premarket trading.

Related stories